Reporting, analysis and commentary on Wegovy from Speedway Scene, drawn together from across our coverage.
3.8 million Medicare beneficiaries can now obtain Wegovy, Zepbound, or the new pill Foundayo for weight loss at a flat $50 monthly copay under a Bridge program that began July 1, 2026, the first obesity-drug coverage in over two decades.
This archive gathers Speedway Scene coverage of Wegovy, bringing together the reporting, analysis and commentary connected to the subject.
The essential morning briefing on the markets, business and world developments that shape the day ahead.
